Dr Jane Wolstenholme
BA(Hons) (London), MSc (York), PhD (Nottingham)
Senior Health Economist, HERC
Jane Wolstenholme has 20 years of experience of conducting economic evaluations for health policy makers and exploring methodological issues relating to the design and analysis of economic evaluations. She has been a health economist at HERC since 1998.
Her main interests include designing and conducting economic evaluations alongside trials and cost-effectiveness models. She is principal investigator and co-applicant on a wide variety of funded research projects, across a number of disease areas and health-care technologies, including cancer, chronic kidney disease, obesity, mental health, point of care diagnostics. She is a health economics advisor for the RDS South Central and for the NIHR Diagnostics Evidence Co-Operative, Oxford. She supervises MSc and DPhil students. Jane has published widely and is co-author of a major OUP text book ‘Applied Methods of Cost-effectiveness Analysis in Health Care’.
Improving outcomes for women diagnosed with early breast cancer through Adherence to adjuvant endocrine therapy (SWEET)
Sharp L. et al, (2020), BREAST CANCER RESEARCH AND TREATMENT, 180, 544 - 545
A randomised controlled trial of Partial prostate Ablation versus Radical prosTatectomy (PART) in intermediate risk, unilateral clinically localised prostate cancer: a feasibility study
Hamdy FC. et al, (2018), Health Technology Assesment, 22, 1 - 96
Partial ablation versus radical prostatectomy in intermediate-risk prostate cancer: the PART feasibility RCT.
Hamdy FC. et al, (2018), Health Technol Assess, 22, 1 - 96
Preference-based measures to obtain health state utility values for use in economic evaluations with child-based populations: a review and UK-based focus group assessment of patient and parent choices.
Wolstenholme JL. et al, (2018), Qual Life Res, 27, 1769 - 1780
Systematic literature review of methodologies and data sources of existing economic models across the full spectrum of Alzheimer's disease and dementia from apparently healthy through disease progression to end of life care: a systematic review protocol.
Karagiannidou M. et al, (2018), BMJ Open, 8